Alvotech Shares Climb After FDA Concludes Facility Inspection
By Dean Seal
Shares of Alvotech jumped after the company said its drug candidates AVT02 and AVT04 could be approved in the coming months now that U.S. regulators have concluded their inspection of its Iceland facility.
The stock was up 11% at $13.60 in early trading. Shares are now up more than 16% since the start of the year.
The biotech company said Friday that the U.S. Food and Drug Administration has completed its facility reinspection and submitted just one observation to Alvotech, which the company expects to respond to in the days to come.
"We believe that the observation is readily addressable, and we intend to respond as quickly as possible," Chief Executive Robert Wessman said.
Based on the conclusion of the reinspection, Alvotech believes it is positioned to receive approval in the U.S. for AVT02, a biosimilar candidate to Abbvie's Humira, by Feb. 24 and for AVT04, a biosimilar to Janssen Pharmaceuticals' Stelara, by April 16.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
January 19, 2024 12:16 ET (17:16 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track